These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 38451524)
1. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524 [TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
4. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis. Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis. Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945 [TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
8. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials. Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L Front Immunol; 2024; 15():1359302. PubMed ID: 38646542 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer. Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178 [TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842 [TBL] [Abstract][Full Text] [Related]
13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053 [TBL] [Abstract][Full Text] [Related]
14. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Wu Y; Hu L; Zhang S; Zhang H Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482 [No Abstract] [Full Text] [Related]
15. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Zhao Z; Gao Y; Xue Q; Gao S; He J Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556 [TBL] [Abstract][Full Text] [Related]
17. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review. Christopoulos P Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058 [TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pasqualotto E; Moraes FCA; Chavez MP; Souza MEC; Rodrigues ALSO; Ferreira ROM; Lopes LM; Almeida AM; Fernandes MR; Santos NPCD Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958317 [No Abstract] [Full Text] [Related]
19. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182 [TBL] [Abstract][Full Text] [Related]
20. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis. Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]